Trial Profile
A Pilot Phase IIa, Multicentre, Open, Proof-of-concept Study on the Safety and the Efficacy of Allogeneic Osteoblastic Cells (ALLOB) Implantation in Rescue Interbody Fusion
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Dec 2022
Price :
$35
*
At a glance
- Drugs Allogeneic osteoblastic cell therapy Bone Therapeutics (Primary) ; Allogeneic osteoblastic cell therapy Bone Therapeutics (Primary)
- Indications Intervertebral disc degeneration
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms ALLOB-RIF1
- Sponsors BioSenic
- 11 Jun 2020 According to a Bone Therapeutics media release, the company expects to report 2-year follow-up period results from this study in the second half of 2020.
- 09 Jun 2020 Status changed from active, no longer recruiting to discontinued.
- 28 May 2020 This trial has been completed (Global End Date: 25 May 2020), according to European Clinical Trials Database record.